Glycotest, Inc.
PrivateLast Round
Seed Round
Jun 30, 2026
Est. Valuation
$25M
Total Funding Raised
$13.81M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Glycotest, Inc. operates in Healthcare & Life Sciences and is based in Pennsylvania. Its latest recorded funding round was a VC Round in January 2024.
Glycotest, Inc. is a diagnostics company that specializes in the commercialization of non-invasive blood tests for the early detection of liver cancers and fibrosis-cirrhosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glycotest, Inc. Comparables
Compare Glycotest, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Helio Genomics | 88% | |
| ImCare Biotech, Inc. | 87% | |
| Hepta Bio | 82% |
For institutional investors. Book with your work email.
Glycotest, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jun 30, 2026 | ||||
| VC Round | Jan 23, 2024 | ||||
| Convertible Debt | May 2, 2023 | ||||
| Series A Extension | Nov 21, 2019 | ||||
| Series A | Oct 22, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Glycotest, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EMV Capital | Series A Extension, VC Round, Series A, Seed Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
$3.2M round led by EMV Capital
- May 18, 2026
Monthly visitors increased 118% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 13, 2026
On Oct 13th '26, Glycotest, Inc. licenses intellectual property from Zucker Institute For Innovation Commercialization that supports expanding its LRAGG biomarker into multi-biomarker panels, receiving exclusive worldwide rights while Zucker Institute For Innovation Commercialization receives royalties on future product sales and other financial consideration.
For institutional investors. Book with your work email.
Glycotest, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Glycotest, Inc.'s valuation, stock price, and market status.
Is Glycotest, Inc. a public or private company?
Glycotest, Inc. is a private company.
What is the current stock price of Glycotest, Inc.?
Glycotest, Inc. is a private company, so its shares have no public market price. Caplight tracks Glycotest, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Glycotest, Inc. worth (valuation)?
Glycotest, Inc.'s valuation is estimated at $25.0M based on funding round data.
Can I buy Glycotest, Inc. stock?
Glycotest, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Glycotest, Inc.'s last funding round?
Glycotest, Inc.'s most recent funding round was Seed Round on June 30, 2026.
Who are the main investors in Glycotest, Inc.?
Key investors in Glycotest, Inc. include EMV Capital.
Will Glycotest, Inc. IPO soon?
No public IPO plans have been announced for Glycotest, Inc..
How can I track Glycotest, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Glycotest, Inc.'s shares on secondary markets.